Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Post-myocardial infarction (MI) patients with ventricular tachycardia (VT) are considered at risk for VT recurrence and sudden cardiac death (SCD). Recent guidelines indicate that in selected patients catheter ablation should be considered instead of an implantable cardioverter-defibrillator (ICD).

Objectives: This study aimed to analyze outcomes of patients referred for VT ablation according to left ventricular ejection fraction (LVEF), tolerance of VT, and acute ablation outcome.

Methods: Post-MI patients without prior ICD undergoing VT ablation at a single center between 2009 and 2022 were included. Patients who presented with tolerated VT and who had an LVEF >35% were offered catheter ablation as first-line therapy. ICD implantation was offered to all patients but was subject to shared decision according to clinical presentation, LVEF, and ablation outcome.

Results: Eighty-six patients (mean age 69 ± 9 years, 84% male, mean LVEF 41 ± 9%) underwent VT ablation. In 66 patients, LVEF was >35%, of whom 51 had tolerated VT. Of these 51 patients, 37 (73%) were rendered noninducible. In 5 of 37 noninducible and in 11 of 14 inducible patients, an ICD was implanted. During a median follow-up of 40 months (Q1-Q3: 24-70 months), 10 of 86 patients had VT recurrence. The overall mortality was 27%, and 1 patient with ICD died suddenly. Among the 37 patients (none on antiarrhythmic drugs) with LVEF >35%, tolerated VT, and noninducibility, no SCD or VT recurrence occurred. Among the 14 patients with LVEF >35%, tolerated VT, and inducibility after ablation, no SCD occurred, but VT recurred in 29%.

Conclusions: Post-MI patients with LVEF >35%, tolerated VT, and noninducibility after ablation have an excellent prognosis. Deferring ICD implantation seems to be safe in these patients.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacep.2024.06.027DOI Listing

Publication Analysis

Top Keywords

lvef >35%
20
patients
16
>35% tolerated
16
post-mi patients
12
patients lvef
12
ablation
10
lvef
9
tolerated lvef
8
catheter ablation
8
icd implantation
8

Similar Publications

Aim     To determine the prevalence and predictors for the development of newly diagnosed chronic heart failure (CHF) in patients with shortness of breath in long-term post-COVID syndrome.Material and methods            This screening cross-sectional clinical study was performed from April 2020 through April 2024, in two stages in an outpatient setting. At the first stage, 878 patients with shortness of breath were screened three or more months after COVID-19, and the presence of at least three diagnostic criteria for CHF, that were not in their history, was verified.

View Article and Find Full Text PDF

Background: Long-term outcomes of transcatheter mitral valve edge-to-edge repair (TEER) are compared with medical therapy remain under investigation. This study evaluated the 3-year effects of MitraClip on mitral regurgitation (MR) severity, ventricular remodeling, and clinical outcomes in high surgical-risk patients.

Methods: A single-center retrospective cohort included 31 MitraClip patients (2016-2023) and 30 contemporaneous controls on maximally tolerated guideline-directed medical therapy.

View Article and Find Full Text PDF

Background: Peripartum cardiomyopathy (PPCM) is a rare, life-threatening form of heart failure occurring in late pregnancy or postpartum, with variable clinical course and outcomes. We report preliminary clinical and echocardiographic findings from a national Italian registry of PPCM patients METHODS: The study was approved by the institutional Ethics Committee and registered at ClinicalTrials.gov (NCT05878041).

View Article and Find Full Text PDF

Aims: The diagnosis of peripartum cardiomyopathy (PPCM) is often delayed due to the absence of disease-specific biomarkers. Recently, serum proteins-QSOX1, adiponectin (ADIPOQ) and ITIH3-have shown potential for improving diagnostic accuracy, especially when used with NT-proBNP. However, the influence of ethnicity on their expression remains unclear.

View Article and Find Full Text PDF

Catecholamine-induced cardiomyopathy secondary to paraganglioma is a rare and potentially reversible condition. However, the course of recovery post-resection remains variable and may be delayed despite biochemical cure. We present the case of a 47-year-old male with biopsy-confirmed extra-adrenal paraganglioma who developed acute decompensated heart failure due to catecholamine-induced cardiomyopathy (left ventricular ejection fraction (LVEF) 30-35%) and multiorgan dysfunction.

View Article and Find Full Text PDF